Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Operating Expenses (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Operating Expenses for 7 consecutive years, with $22.7 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 16.8% to $22.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $84.8 million through Dec 2025, down 16.81% year-over-year, with the annual reading at $84.8 million for FY2025, 16.81% down from the prior year.
  • Operating Expenses for Q4 2025 was $22.7 million at Fulcrum Therapeutics, up from $21.9 million in the prior quarter.
  • The five-year high for Operating Expenses was $36.1 million in Q2 2022, with the low at $19.4 million in Q4 2024.
  • Average Operating Expenses over 5 years is $26.0 million, with a median of $26.6 million recorded in 2021.
  • The sharpest move saw Operating Expenses soared 50.09% in 2022, then tumbled 32.69% in 2024.
  • Over 5 years, Operating Expenses stood at $28.6 million in 2021, then grew by 0.14% to $28.7 million in 2022, then grew by 0.72% to $28.9 million in 2023, then tumbled by 32.69% to $19.4 million in 2024, then increased by 16.8% to $22.7 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $22.7 million, $21.9 million, and $19.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.